TABLE 5.

Incidence Rates of CVT within 1 month (31 days) from first COVID‐19 Vaccine Dose Administration According to Age Group, Sex, and Vaccine Type using data from Nine States in Germany during the Study Period (January 1, 2021 to April 14, 2021)

Age group (years)	Vaccine	Sex	Total doses administered	Estimated total first doses administered	Cases	Person‐months	Rate per 100,000 person‐months (95% CI)
<60	ChAdOx1	female	1061837	1061837	20	972176.92	2.06 (1.26–3.18)
<60	ChAdOx1	non‐female	449910	449910	3	398843.47	0.75 (0.16–2.20)
<60	BNT162b2	female	1354788	809594	2	648841.26	0.31 (0.04–1.11)
<60	BNT162b2	non‐female	709366	451270	1	334136.79	0.30 (0.01–1.67)
<60	mRNA‐1273	female	163110	105570	0	77394.11	0.00 (0.00–4.77)
<60	mRNA‐1273	non‐female	100068	70190	0	47423.16	0.00 (0.00–7.78)
60+	ChAdOx1	female	423688	423688	4	229652.37	1.74 (0.47–4.46)
60+	ChAdOx1	non‐female	385100	385100	0	175064.52	0.00 (0.00–2.11)
60+	BNT162b2	female	3171936	1889033	1	1548276.66	0.06 (0.00–0.36)
60+	BNT162b2	non‐female	2154103	1304608	0	1051007.4	0.00 (0.00–0.35)
60+	mRNA‐1273	female	161178	100096	0	71429.39	0.00 (0.00–5.16)
60+	mRNA‐1273	non‐female	121116	75538	0	53204.68	0.00 (0.00–6.93)

CI = confidence interval.